Vera Therapeutics, Inc. - 8-K Filing
Vera Therapeutics announced on July 7, 2026 that the U.S. Food and Drug Administration granted accelerated approval for TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of disease progression. (Items: 8.01 Other Events)
Tickers: $VERA